AlloMek Therapeutics

United States
Connecticut, Farmington, United States
203-208-2811 ★

Company profile

AlloMek Therapeutics company profile

Allomek Therapeutics is a privately held pharmaceutical company committed to helping cancer patients by the discovery and development of targeted therapies. Allomek’s primary interest lies in the inhibition of targets associated with the Ras pathway. Allomek has discovered a novel class of MEK kinase inhibitors that improve the biopharmaceutical properties of previous MEK inhibitors. Allomek’s clinical candidate, CIP-1374, is an allosteric MEK kinase inhibitor that combines potent activity against MEK1/2 kinase and against chemo-resistant ovarian cancer stem cells.

Business identity

Contact email
[email protected]
Phone number
203-208-2811
Operating status
Closed
Company type
For Profit

Headquarters

Headquarters
Connecticut, Farmington, United States
Postal code
06032
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
1
Total equity funding
$150K
Last funding
Pre Seed / $150K / 2013-05-20
Last equity funding
Pre Seed / $150K
Investors
1
Founders
1
Closed on
2022-10-12
Exited on
2022-10-12

Founders and investors

Founders

Uday Khire

Investors

Connecticut Innovations

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.